Valneva Shares Slide to €2.39, Approaching Critical Support at €2.26

The Stock Continues Its Slide Following a Reorganization Plan Announced Last Week

Valneva is down 1.96% at €2.3980, ranking among the largest declines in the SBF 120, while the broader index gains 0.56%. The weekly loss reaches 5.22%, and the stock has fallen nearly 48% over three months. This movement follows the publication of the first quarter accounts on May 13. The company reported a 37% decline in revenue and a net loss of €32.1 million, compared to €9.2 million a year earlier. Concurrently, the group unveiled a reorganization plan aimed at reducing its operational expenses by 25 to 35% and its global workforce by 10 to 15%. During this announcement, Valneva adjusted its 2026 revenue forecast to between €135 and €150 million, citing a decline in third-party product sales and unfavorable trends in travel vaccines. The capital context remains challenging: the biotech completed a reserved offer of €84 million at the end of April, with €37 million at closing and up to €47 million contingent on the exercise of warrants.

The Stock is 1.32% Below its 20-Day Moving Average and Close to the €2.26 Support

The stock is below its 20-day moving average (€2.43), and the gap widens with longer averages: the 50-day MA is 20.86% above the current price, the 200-day MA more than 37% above. This configuration indicates a bearish trend that has been established for several months. The RSI at 41 remains in the neutral zone, with no pronounced oversold signal despite the accumulated decline. The €2.26 support, already tested at the beginning of May, is now less than 6% from the current price. The next important event is scheduled for May 21 with the company's participation in the Bernstein European Small & Mid-Cap Conference. The general meeting will be held on June 25, and the semi-annual results for 2026 are expected on August 13.